Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses.
Year: 2012
Type: article
Study design: Clinical Trial
Source: PubMed
DOI: 10.3275/7869
Authors: P Ferolla, A Faggiano, F Grimaldi, D Ferone, G Scarpelli, V Ramundo, R Severino, M C Bellucci, L M Camera, G Lombardi, G Angeletti, A Colao
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W112281575
